文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

度普利尤单抗治疗血液嗜酸性粒细胞计数≥500 细胞·微升的哮喘患者的疗效和安全性。

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL.

机构信息

LungenClinic Grosshansdorf, member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Grosshansdorf, Germany

Christian-Albrechts University, member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Kiel, Germany.

出版信息

Eur Respir J. 2022 Jun 23;59(6). doi: 10.1183/13993003.02577-2021. Print 2022 Jun.

DOI:10.1183/13993003.02577-2021

PMID:35487538

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9218240/

Abstract

https://bit.ly/3Jxvicb

摘要

链接

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2328/9218240/a0d9589d4a67/ERJ-02577-2021.01.jpg

相似文献

1

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL.度普利尤单抗治疗血液嗜酸性粒细胞计数≥500 细胞·微升的哮喘患者的疗效和安全性。

Eur Respir J. 2022 Jun 23;59(6). doi: 10.1183/13993003.02577-2021. Print 2022 Jun.

2

Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy.度普利尤单抗治疗未控制哮喘患者：2型生物标志物可能是治疗疗效的预测指标。

J Asthma. 2020 Jan;57(1):79-81. doi: 10.1080/02770903.2018.1545857. Epub 2019 Mar 1.

3

Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?重度哮喘中血液嗜酸性粒细胞的减少/清除：是否应考虑安全性？

Expert Opin Biol Ther. 2022 Mar;22(3):377-384. doi: 10.1080/14712598.2021.1960977. Epub 2021 Aug 10.

4

Dupilumab (Dupixent) for Asthma.度普利尤单抗（达必妥）用于治疗哮喘。

Am Fam Physician. 2020 Feb 15;101(4):244-245.

5

Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review.比较度普利尤单抗和本那鲁单抗治疗未充分控制的哮喘患者的疗效和安全性：系统评价。

Int J Mol Sci. 2020 Jan 30;21(3):889. doi: 10.3390/ijms21030889.

6

Eosinophils, beyond IL-5.嗜酸性粒细胞，不仅仅与白细胞介素 5 相关。

Cells. 2021 Oct 1;10(10):2615. doi: 10.3390/cells10102615.

7

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.血清 IgE 浓度预测重度嗜酸性粒细胞性哮喘患者恶化风险和 benralizumab 疗效的能力。

Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.

8

Tezepelumab (Tezspire) for severe asthma.用于重度哮喘的tezepelumab（Tezspire）。

Med Lett Drugs Ther. 2022 Feb 21;64(1644):25-26.

9

Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma.血清白介素-18 水平低可能预示着度普利尤单抗治疗重度哮喘的疗效。

Intern Med. 2024 Jan 15;63(2):179-187. doi: 10.2169/internalmedicine.1808-23. Epub 2023 May 24.

10

For the Patient.给患者的。

Allergy Asthma Proc. 2018 Sep 1;39(5):398. doi: 10.2500/aap.2013.39.4170.

引用本文的文献

1

Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.嗜酸性粒细胞驱动型与嗜酸性粒细胞相关型重度哮喘：靶向治疗的实际意义

Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729.

2

Increased Muc5AC and Decreased Ciliated Cells in Severe Asthma Partially Restored by Inhibition of IL-4Rα Receptor.严重哮喘中Muc5AC增加和纤毛细胞减少通过抑制IL-4Rα受体得到部分恢复。

Am J Respir Crit Care Med. 2024 Dec 15;210(12):1409-1420. doi: 10.1164/rccm.202307-1266OC.

3

The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.

本文引用的文献

1

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.度普利尤单抗可改善未得到控制的中重度哮喘患者的肺功能。

ERJ Open Res. 2020 Jan 27;6(1). doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.

2

Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.使用IL-4Rα抗体度普利尤单抗对IL-4和IL-13进行双重阻断，对于广泛抑制2型炎症是必需的。

Allergy. 2020 May;75(5):1188-1204. doi: 10.1111/all.14151. Epub 2020 Jan 3.

3

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.

度普利尤单抗治疗血液嗜酸性粒细胞计数≥500 细胞·微升的哮喘患者的疗效和安全性。

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL.

机构信息

LungenClinic Grosshansdorf, member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Grosshansdorf, Germany

Christian-Albrechts University, member of the German Center for Lung Research (DZL), Airway Research Center North (ARCN), Kiel, Germany.

出版信息

Eur Respir J. 2022 Jun 23;59(6). doi: 10.1183/13993003.02577-2021. Print 2022 Jun.

DOI:10.1183/13993003.02577-2021

PMID:35487538

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9218240/

Abstract

https://bit.ly/3Jxvicb

摘要

链接

相似文献

1

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL.度普利尤单抗治疗血液嗜酸性粒细胞计数≥500 细胞·微升的哮喘患者的疗效和安全性。

Eur Respir J. 2022 Jun 23;59(6). doi: 10.1183/13993003.02577-2021. Print 2022 Jun.

2

Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy.度普利尤单抗治疗未控制哮喘患者：2型生物标志物可能是治疗疗效的预测指标。

J Asthma. 2020 Jan;57(1):79-81. doi: 10.1080/02770903.2018.1545857. Epub 2019 Mar 1.

3

Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?重度哮喘中血液嗜酸性粒细胞的减少/清除：是否应考虑安全性？

Expert Opin Biol Ther. 2022 Mar;22(3):377-384. doi: 10.1080/14712598.2021.1960977. Epub 2021 Aug 10.

4

Dupilumab (Dupixent) for Asthma.度普利尤单抗（达必妥）用于治疗哮喘。

Am Fam Physician. 2020 Feb 15;101(4):244-245.

5

Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review.比较度普利尤单抗和本那鲁单抗治疗未充分控制的哮喘患者的疗效和安全性：系统评价。

Int J Mol Sci. 2020 Jan 30;21(3):889. doi: 10.3390/ijms21030889.

6

Eosinophils, beyond IL-5.嗜酸性粒细胞，不仅仅与白细胞介素 5 相关。

Cells. 2021 Oct 1;10(10):2615. doi: 10.3390/cells10102615.

7

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.血清 IgE 浓度预测重度嗜酸性粒细胞性哮喘患者恶化风险和 benralizumab 疗效的能力。

Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.

8

Tezepelumab (Tezspire) for severe asthma.用于重度哮喘的tezepelumab（Tezspire）。

Med Lett Drugs Ther. 2022 Feb 21;64(1644):25-26.

9

Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma.血清白介素-18 水平低可能预示着度普利尤单抗治疗重度哮喘的疗效。

Intern Med. 2024 Jan 15;63(2):179-187. doi: 10.2169/internalmedicine.1808-23. Epub 2023 May 24.

10

For the Patient.给患者的。

Allergy Asthma Proc. 2018 Sep 1;39(5):398. doi: 10.2500/aap.2013.39.4170.

引用本文的文献

1

Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.嗜酸性粒细胞驱动型与嗜酸性粒细胞相关型重度哮喘：靶向治疗的实际意义

Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729.

2

Increased Muc5AC and Decreased Ciliated Cells in Severe Asthma Partially Restored by Inhibition of IL-4Rα Receptor.严重哮喘中Muc5AC增加和纤毛细胞减少通过抑制IL-4Rα受体得到部分恢复。

Am J Respir Crit Care Med. 2024 Dec 15;210(12):1409-1420. doi: 10.1164/rccm.202307-1266OC.

3

The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.

本文引用的文献

1

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.度普利尤单抗可改善未得到控制的中重度哮喘患者的肺功能。

ERJ Open Res. 2020 Jan 27;6(1). doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.

2

Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.使用IL-4Rα抗体度普利尤单抗对IL-4和IL-13进行双重阻断，对于广泛抑制2型炎症是必需的。

Allergy. 2020 May;75(5):1188-1204. doi: 10.1111/all.14151. Epub 2020 Jan 3.

3

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.

IL-4/IL-13 在嗜酸性粒细胞为主的重症哮喘发病中的可能作用

Biomolecules. 2024 May 2;14(5):546. doi: 10.3390/biom14050546.

4

Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China.度普利尤单抗治疗重度哮喘的疗效及度普利尤单抗诱导的嗜酸性粒细胞增多症的危险因素：一项来自中国的初步研究。

Ann Med. 2024 Dec;56(1):2311843. doi: 10.1080/07853890.2024.2311843. Epub 2024 Feb 5.

5

Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma.度普利尤单抗抑制伴有严重哮喘的复发性慢性嗜酸性粒细胞性肺炎。

Nagoya J Med Sci. 2023 Nov;85(4):857-865. doi: 10.18999/nagjms.85.4.857.

6

Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals.重度真菌性哮喘：生物制剂和吸入性抗真菌药物的作用

J Fungi (Basel). 2023 Jan 6;9(1):85. doi: 10.3390/jof9010085.

度普利尤单抗在未控制的中重度过敏性哮喘患者中的疗效。

J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12.

4

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.度普利尤单抗治疗糖皮质激素依赖型重症哮喘的疗效和安全性。

N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21.

5

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.度普利尤单抗在中重度未控制哮喘中的疗效和安全性。

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

6

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.血液嗜酸性粒细胞作为哮喘和 COPD 治疗选择的生物标志物。

Curr Drug Targets. 2018;19(16):1882-1896. doi: 10.2174/1389450119666180212120012.

7

Commonality of the IL-4/IL-13 pathway in atopic diseases.特应性疾病中白细胞介素-4/白细胞介素-13通路的共性

Expert Rev Clin Immunol. 2017 May;13(5):425-437. doi: 10.1080/1744666X.2017.1298443. Epub 2017 Mar 15.

8

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.度普利尤单抗在吸入中至高剂量皮质类固醇激素联合长效β2 激动剂治疗控制不佳的持续性哮喘成人患者中的疗效和安全性：一项随机、双盲、安慰剂对照的 2b 期关键剂量范围研究。

Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.

9

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.血液嗜酸性粒细胞计数与未来年度哮喘疾病负担：一项英国队列研究。

Lancet Respir Med. 2015 Nov;3(11):849-58. doi: 10.1016/S2213-2600(15)00367-7. Epub 2015 Oct 19.

10

Biomarkers in the Management of Difficult Asthma.难治性哮喘管理中的生物标志物

Curr Top Med Chem. 2016;16(14):1561-73. doi: 10.2174/1568026616666151015093406.

Suppr 超能文献

文献检索

文件翻译

深度研究

Suppr 超能文献

文献检索

文件翻译

深度研究

度普利尤单抗治疗血液嗜酸性粒细胞计数≥500 细胞·微升的哮喘患者的疗效和安全性。

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL.

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

度普利尤单抗治疗血液嗜酸性粒细胞计数≥500 细胞·微升的哮喘患者的疗效和安全性。

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL.

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献